Could a Weight-Loss drug ease chronic back pain? a trial investigates

NCT ID NCT07731256

Not yet recruiting Symptom relief Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether semaglutide, a weekly injection already used for weight loss, can reduce chronic low back pain in adults with obesity. Researchers will compare semaglutide to a placebo over 52 weeks in 250 participants, measuring changes in pain severity, disability, and quality of life. The goal is to see if the drug's effects on weight and inflammation translate into meaningful pain relief.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide, a GLP-1 receptor agonist drug given as a weekly injection
What this could lead to: If it works, this could offer a new treatment option for chronic low back pain in people with obesity, potentially reducing pain and improving quality of life.
What could go wrong: This is a phase 2 trial, so results are still uncertain. Semaglutide can cause side effects like nausea and vomiting, and it is not yet known if any pain relief will be meaningful or lasting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LOWER BACK PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Low Back Pain Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LOWER BACK PAIN GLP1 AGONIST LOWER BACK PAIN OBESITY (BMI>30)

Contacts and locations

Locations

The University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
Washington University School of Medicine

St Louis, Missouri, 63108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.